野生型(正常)KRAS遺伝子の存在はこれらの薬の有効性を保障しないが、数多くの大規模研究[18][19]は、KRAS野生型腫瘍を持つmCRC(転移性大腸癌)患者に対してセツキシマブ顕著な効果を示すことが明らかにされている。2009年に発表された、第III相CRYSTAL試験(Cetuximab combined with iRinotecan in first-line therapY for metaSTatic colorectAL cancer:切除不能再発大腸がんのファーストライン療法においてイリノテカンと併用したセツキシマブ)では、セツキシマブと抗がん剤の組合せで治療した野生型KRAS遺伝子を持つ患者は、抗がん剤のみで治療した患者と比較して59%にものぼる奏効率を示した。また、KRAS野生型遺伝子を持つ患者では、化学療法のみを受けた患者と比較して病気の進行のリスクが32%低下した[19]。
^Tsuchida N, Ryder T, Ohtsubo E (1982). “Nucleotide sequence of the oncogene encoding p21 transforming protein of Kirsten murine sarcoma virus”. Science217: 937-939. PMID6287573.
^Shimizu K, Birnbaum D, Ruley MA, Fasano O, Suard Y, Edlund L, Taparowsky E, Goldfarb M, Wigler M. (1983). “Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1.”. Nature.304 (5926): 497-500. PMID6308465.
^ McGrath JP, Capon DJ, Smith DH, Chen EY, Seeburg PH, Goeddel DV, Levinson AD (1983). “Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene”. Nature304 (5926): 501–6. doi:10.1038/304501a0. PMID6308466.
^Popescu NC, Amsbaugh SC, DiPaolo JA, Tronick SR, Aaronson SA, Swan DC (March 1985). “Chromosomal localization of three human ras genes by in situ molecular hybridization”. Somat. Cell Mol. Genet.11 (2): 149–55. doi:10.1007/BF01534703. PMID3856955.
^Schubbert S, Zenker M, Rowe SL, et al. (2006). “Germline KRAS mutations cause Noonan syndrome”. Nat. Genet.38 (3): 331–6. doi:10.1038/ng1748. PMID16474405.
^Niihori T, Aoki Y, Narumi Y, et al. (2006). “Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome”. Nat. Genet.38 (3): 294–6. doi:10.1038/ng1749. PMID16474404.
^Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988). “Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes”. Cell53 (4): 549–54. doi:10.1016/0092-8674(88)90571-5. PMID2453289.
^Tam IY, Chung LP, Suen WS, et al. (2006). “Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features”. Clin. Cancer Res.12 (5): 1647–53. doi:10.1158/1078-0432.CCR-05-1981. PMID16533793.
^Vogelstein B, Kinzler KW (2004). “Cancer genes and the pathways they control”. Nat. Med.10 (8): 789-99. doi:10.1038/nm1087. PMID15286780.
^Lièvre A, Bachet JB, Le Corre D, et al. (2006). “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer”. Cancer Res.66 (8): 3992–5. doi:10.1158/0008-5472.CAN-06-0191. PMID16618717.
^Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (February 2009). “Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer”. J. Clin. Oncol.27 (5): 663–71. doi:10.1200/JCO.2008.20.8397. PMID19114683.
^ abVan Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (April 2009). “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer”. N. Engl. J. Med.360 (14): 1408–17. doi:10.1056/NEJMoa0805019. PMID19339720.
^ abSuda K, Tomizawa K, Mitsudomi T (March 2010). “Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation”. Cancer Metastasis Rev.29 (1): 49–60. doi:10.1007/s10555-010-9209-4. PMID20108024.
^Riely GJ, Marks J, Pao W (April 2009). “KRAS mutations in non-small cell lung cancer”. Proc Am Thorac Soc6 (2): 201–5. doi:10.1513/pats.200809-107LC. PMID19349489.
^Kiyono M, Kato J, Kataoka T, Kaziro Y, Satoh T (September 2000). “Stimulation of Ras guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) upon tyrosine phosphorylation by the Cdc42-regulated kinase ACK1”. J. Biol. Chem.275 (38): 29788–93. doi:10.1074/jbc.M001378200. PMID10882715.
^Rubio I, Wittig U, Meyer C, Heinze R, Kadereit D, Waldmann H, Downward J, Wetzker R (November 1999). “Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma”. Eur. J. Biochem.266 (1): 70–82. doi:10.1046/j.1432-1327.1999.00815.x. PMID10542052.
^Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ (July 2003). “RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor”. J. Biol. Chem.278 (30): 28045–51. doi:10.1074/jbc.M300554200. PMID12732644.
Tsuchida N, Murugan AK, Grieco M. (2016). “Kirsten Ras oncogene : significance of its discovery in human cancer research”. Oncotarget7 (29): 46717-33. PMID27102293.
Kahn S, Yamamoto F, Almoguera C, et al. (1987). “The c-K-ras gene and human cancer (review).”. Anticancer Res.7 (4A): 639–52. PMID3310850.
Yamamoto F, Nakano H, Neville C, Perucho M (1985). “Structure and mechanisms of activation of c-K-ras oncogenes in human lung cancer.”. Prog. Med. Virol.32: 101–14. PMID3895297.
Porta M, Ayude D, Alguacil J, Jariod M (2003). “Exploring environmental causes of altered ras effects: fragmentation plus integration?”. Mol. Carcinog.36 (2): 45–52. doi:10.1002/mc.10093. PMID12557259.
Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O (2006). “Control of colorectal metastasis formation by K-Ras.”. Biochim. Biophys. Acta1756 (2): 103–14. doi:10.1016/j.bbcan.2005.07.001. PMID16098678.
Castagnola P, Giaretti W (2006). “Mutant KRAS, chromosomal instability and prognosis in colorectal cancer.”. Biochim. Biophys. Acta1756 (2): 115–25. doi:10.1016/j.bbcan.2005.06.003. PMID16112461.
Deramaudt T, Rustgi AK (2006). “Mutant KRAS in the initiation of pancreatic cancer.”. Biochim. Biophys. Acta1756 (2): 97–101. doi:10.1016/j.bbcan.2005.08.003. PMID16169155.
Su YH, Wang M, Aiamkitsumrit B, et al. (2007). “Detection of a K-ras mutation in urine of patients with colorectal cancer.”. Cancer biomarkers : section a of Disease markers1 (2–3): 177–82. PMID17192038.